Download PDF
Semin Thromb Hemost 2005; 31(4): 420-425
DOI: 10.1055/s-2005-916677
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Detection of Aspirin Resistance by PFA-100: Prevalence and Aspirin Compliance in Patients with Chronic Stable Angina

Basil Crowe1 , Syed Abbas2 , Brendan Meany2 , Jacob de Haan3 , Mary R. Cahill1 , 4
  • 1Department of Hematology, Mid Western Regional Hospital, Dooradoyle, Limerick, Ireland
  • 2Department of Cardiology, Mid Western Regional Hospital, Dooradoyle, Limerick, Ireland
  • 3Dade Behring, Marburg, Germany
  • 4Consultant Haematologist
Further Information

Publication History

Publication Date:
07 September 2005 (online)

    Permissions and Reprints

ABSTRACT

Most acute coronary syndromes result from a platelet-rich occlusion of the coronary arteries. Antiplatelet drugs are of proven efficacy in preventing myocardial infarction, unstable angina, and stroke. However, not all patients on aspirin (ASA) benefit. We studied the phenomenon of aspirin resistance with a simple and reliable platelet function analyzer-the PFA-100. Studying 31 patients with unstable angina and 105 controls, we found aspirin resistance in 42% of patients, most of whom were shown to be compliant utilizing concomitant salicylate levels.

KEYWORDS

Platelets - platelet activation - PFA-100 - nitrates - aspirin resistance - salicylate levels

REFERENCES

  • 1 Kannel W B. Bishop Lecture: Contribution of the Framingham Study to preventive cardiology.  J Am Coll Cardiol. 1990;  15 206-211
    PubMedGoogle Scholar
  • 2 Heller R F, Chinn S, Pedoe H D, Rose G. How well can we predict coronary heart disease? Findings in the United Kingdom Heart Disease Prevention Project.  BMJ (Clin Res Ed). 1984;  288 1409-1411
    PubMedGoogle Scholar
  • 3 Cairns J A, Gent M, Singer J et al.. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multi-center trial.  N Engl J Med. 1985;  313 1369-1375
    CrossrefPubMedGoogle Scholar
  • 4 Lewis Jr H D, Davis J W, Archibald D G et al.. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study.  N Engl J Med. 1983;  309 396-403
    CrossrefPubMedGoogle Scholar
  • 5 Antithrombotic Trialists' Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for the prevention of death, myocardial infarction, and stroke in high risk patients.  BMJ. 2002;  324 71-86
    CrossrefPubMedGoogle Scholar
  • 6 Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn P F. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men.  Circulation. 1991;  84 613-617
    CrossrefPubMedGoogle Scholar
  • 7 Tofler G H, Brezinski D, Schafer A I et al.. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death.  N Engl J Med. 1987;  316 1514-1518
    CrossrefPubMedGoogle Scholar
  • 8 Vilen L, Johansson S, Kutti J, Cronberg S, Vedin A, Wilhelmsson C. ADP-induced platelet aggregation in young female survivors of acute myocardial infarction and their female controls.  Acta Med Scand. 1985;  217 9-13
    PubMedGoogle Scholar
  • 9 [No authors listed] . Secondary prevention of vascular disease by prolonged antiplatelet treatment.  Antiplatelet Trialists Collaboration.  Br Med J (Clin Res Ed). 1988;  296 320-331
    PubMedGoogle Scholar
  • 10 Buchanan M R, Brister S J. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically.  Can J Cardiol. 1995;  11 221-227
    PubMedGoogle Scholar
  • 11 Helgason C M, Bolin K M, Hoff J A et al.. Development of aspirin resistance in persons with previous ischemic stroke.  Stroke. 1994;  25 2331-2336
    CrossrefPubMedGoogle Scholar
  • 12 Cahill M, Mistry R, Chapman C, Barnett D B. Effects of age, sex, and oral contraceptives on the platelet membrane fibrinogen binding site (glycoprotein IIb/IIIa).  Br J Clin Pharmacol. 1992;  33 11-15
    PubMedGoogle Scholar
  • 13 Cahill M R, Macey M G, Newland A C. Fixation with formaldehyde induces expression of activation dependent platelet membrane glycoproteins, P-selectin (CD62) and GP53 (CD63).  Br J Haematol. 1993;  84 527-529
    PubMedGoogle Scholar
  • 14 Harrison P. Progress in the assessment of platelet function.  Br J Haematol. 2000;  111 733-744
    PubMedGoogle Scholar
  • 15 Kundu S K, Heilmann E J, Sio R et al.. Characterization of an in vitro platelet function analyzer, PFA-100™.  Semin Thromb Hemost. 1995;  21 106-112
    PubMedGoogle Scholar
  • 16 Kundu S K, Heilmann E J, Sio R, Garcia C, Davidson R M, Ostgaard R A. Description of an in vitro platelet function function analyzer-PFA-100.  Semin Thromb Hemost. 1995;  21 (suppl 2) 106-112
    PubMedGoogle Scholar
  • 17 Rodgers R P, Levin J. A critical reappraisal of the bleeding time.  Semin Thromb Hemost. 1990;  16 1-20
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Elwood P C, Renaud S, Sharp D S, Beswick A D, O'Brien J R, Yarnell J W. Ischemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study.  Circulation. 1991;  83 38-44
    PubMedGoogle Scholar
  • 19 Zahavi J, Kakkar V V. β-thromboglobulin-a specific marker of in vivo platelet release reaction.  Thromb Haemost. 1980;  44 23-29
    PubMedGoogle Scholar
  • 20 Marshall P W, Williams A J, Dixon R M et al.. A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100, in healthy volunteers.  Br J Clin Pharmacol. 1997;  44 151-155
    CrossrefPubMedGoogle Scholar
  • 21 Cattaneo M, Federici A B, Lecchi A et al.. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease.  Thromb Haemost. 1999;  82 35-39
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Fressinaud E, Veyradier A, Truchaud F et al.. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases.  Blood. 1998;  91 1325-1331
    CrossrefPubMedGoogle Scholar
  • 23 Mammen E F, Comp P C, Gosselin R et al.. PFA-100™ system: a new method for assessment of platelet dysfunction.  Semin Thromb Hemost. 1998;  24 195-202
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Bock M, de Haan J, Beck K-H et al.. Standardization of the PFA-100 platelet function test in 105 mmol/L buffered citrate: effect of gender, smoking, and oral contraceptives.  Br J Haematol. 1999;  106 898-904
    CrossrefPubMedGoogle Scholar
  • 25 Heilmann E J, Kundu S K, Sio R, Garcia C, Gomez R, Christie D J. Comparison of four commercial citrate blood collection systems for platelet function analysis by the PFA-100 system.  Thromb Res. 1997;  87 159-164
    CrossrefPubMedGoogle Scholar
  • 26 Cahill M R, Macey M G, Dawson J R, Newland A C. Prevention of restenosis after angioplasty.  Lancet. 1994;  343 1361
    PubMedGoogle Scholar
  • 27 Fitzgerald D J, Roy L, Catella F, Fitzgerald G A. Platelet activation in unstable coronary disease.  N Engl J Med. 1986;  315 983-989
    CrossrefPubMedGoogle Scholar
  • 28 Hirsh P D, Hillis L D, Campbell W B, Firth B G, Willerson J T. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease.  N Engl J Med. 1981;  304 685-691
    PubMedGoogle Scholar
  • 29 De Boer A C, Turpie A GG, Butt R W, Johnston R V, Genton E. Platelet release and thromboxane synthesis in symptomatic coronary artery disease.  Circulation. 1982;  66 327-333
    PubMedGoogle Scholar
  • 30 Gormsen J, Dalsgaard-Neilsen J, Agerskov-Andersen L. ADP-induced platelet aggregation in vitro in patients with ischaemic heart disease and peripheral thrombo-atherosclerosis.  Acta Med Scand. 1977;  201 509-513
    PubMedGoogle Scholar
  • 31 Gum P A, Kottke-Marchant K, Poggio E D et al.. Profile and prevalence of aspirin resistance in patients with cardiovascular disease.  Am J Cardiol. 2001;  88 230-235
    CrossrefPubMedGoogle Scholar
  • 32 McKee S A, Sane D C, Deliargyris E N. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms and clinical significance.  Thromb Haemost. 2002;  88 711-715
    PubMedGoogle Scholar
  • 33 von Pape K, Aland E, Bohner J. Platelet function analysis with PFA-100 in patients medicated with acetylsalicylic acid strongly depends on concentration of sodium citrate used for anticoagulation of blood samples.  Thromb Res. 2000;  98 295-299
    CrossrefPubMedGoogle Scholar
  • 34 Fitzgerald G A. Parsing an enigma: the pharmacodynamics of aspirin resistance.  Lancet. 2003;  361 542-543
    CrossrefPubMedGoogle Scholar
  • 35 Macchi L, Christiaens L, Brabant S et al.. Resistance in vitro to low-dose aspirin is associated with platelet PLA1 (GP IIIa) polymorphism but not with c807T (GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms.  J Am Coll Cardiol. 2003;  42 1115-1119
    CrossrefPubMedGoogle Scholar
  • 36 MacDonald T M, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin.  Lancet. 2003;  361 573-574
    CrossrefPubMedGoogle Scholar
  • 37 Marcus A J, Broekman M J, Pinsky D J. COX inhibitors and thromboregulation.  N Engl J Med. 2002;  347 1025-1026
    CrossrefPubMedGoogle Scholar

Mary CahillM.D. 

Consultant Haematologist, Department of Haematology, Cork University Hospital

Wilton, Cork, Ireland

Email: mrcahill@iolfree.ie

      >